Neue Studien: Psoriasis im JDDG

Neue Studien: Psoriasis im JDDGhttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/?d=1Neue Studien: Psoriasis im JDDGdeUnterschiedliche anatomische Spezifitäten des residualen PASI bei Biologikatherapien der Psoriasishttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/unterschiedliche-anatomische-spezifit%C3%A4ten-des-residualen-pasi-bei-biologikatherapien-der-psoriasis-r622/No abstract supplied.

]]>622Mon, 25 May 2026 08:01:34 +0000Dermal lipomatous metaplasia in chronic plaque psoriasis: A clinicopathological case report.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/dermal-lipomatous-metaplasia-in-chronic-plaque-psoriasis-a-clinicopathological-case-report-r621/No abstract supplied.

]]>621Mon, 25 May 2026 08:01:34 +0000Dupilumab-Induced Psoriasis in a Patient with Bullous Pemphigoid.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/dupilumab-induced-psoriasis-in-a-patient-with-bullous-pemphigoid-r620/No abstract supplied.

]]>620Thu, 14 May 2026 18:05:27 +0000Safety of biologic therapy in psoriasis patients with a previous malignancy: Retrospective study using TriNetX.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/safety-of-biologic-therapy-in-psoriasis-patients-with-a-previous-malignancy-retrospective-study-using-trinetx-r609/Background and objectivesEvidence-based recommendations for the treatment of patients with psoriatic disease (PsO) and a prior history of malignancy are limited. This study aimed to compare the incidence of newly diagnosed neoplasms among patients with PsO and a previous malignancy receiving treatment with conventional systemic therapies, apremilast, or biologic agents.

Patients and methods

Retrospective observational study using TriNetX. PsO patients (ICD10:L40) with a previous diagnosis of cancer (ICD10:C00-D49) less than 5 years prior to systemic therapy initiation were selected. Outcomes evaluated included new documentation of neoplasms and all-cause mortality.

Results

Patients under biologic therapy had a significantly lower new neoplasm documentation rate and all-cause mortality compared to classical agents (HR 0.857 and HR 0.705, respectively) and apremilast (HR 0.782 and HR 0.803, respectively) at 3 years follow-up. Only TNFi exhibited a significantly lower new neoplasm rate (HR 0.867, p < 0.0001) compared to classical agents; however, all biologic agents significantly decreased mortality. IL-23i was the only biologic therapy to significantly lower cancer recurrence risk (RR 0.878) compared to TNFi, with no differences in all-cause mortality.

Conclusions

Biologic therapy for PsO may represent a safe treatment option in patients with a history of malignancy, compared with conventional systemic therapies or apremilast. Among biologic agents, IL-23 inhibitors appear to be associated with the most favorable safety profile.

]]>609Thu, 23 Apr 2026 06:10:08 +0000Evidence- and consensus-based guideline on lichen sclerosus.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/evidence-and-consensus-based-guideline-on-lichen-sclerosus-r582/Weiterlesen

]]>582Fri, 10 Apr 2026 10:21:31 +0000Evidenz‐ und konsensbasierte (S3) Leitlinie: Lichen sclerosushttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/evidenz%E2%80%90-und-konsensbasierte-s3-leitlinie-lichen-sclerosus-r581/No abstract supplied.

]]>581Fri, 10 Apr 2026 10:21:31 +0000The role of inflammatory cell death in type 1 dominant inflammatory skin diseases.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/the-role-of-inflammatory-cell-death-in-type-1-dominant-inflammatory-skin-diseases-r580/Weiterlesen

]]>580Fri, 10 Apr 2026 10:21:31 +0000Should TNF inhibitors be avoided in psoriasis patients with latent tuberculosis?https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/should-tnf-inhibitors-be-avoided-in-psoriasis-patients-with-latent-tuberculosis-r579/No abstract supplied.

]]>579Fri, 10 Apr 2026 10:21:31 +0000Palmoplantare Pustulose: Entstehung, Differentialdiagnose und Therapiehttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/palmoplantare-pustulose-entstehung-differentialdiagnose-und-therapie-r578/No abstract supplied.

Weiterlesen

]]>578Fri, 10 Apr 2026 10:21:31 +0000Palmoplantar pustulosis: pathogenesis, differential diagnosis, and treatment.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/palmoplantar-pustulosis-pathogenesis-differential-diagnosis-and-treatment-r577/Weiterlesen

]]>577Fri, 10 Apr 2026 10:21:31 +0000Ixekizumab optimization in moderate-to-severe plaque psoriasis in real clinical practice: a retrospective multicenter study.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/ixekizumab-optimization-in-moderate-to-severe-plaque-psoriasis-in-real-clinical-practice-a-retrospective-multicenter-study-r539/No abstract supplied.

Weiterlesen

]]>539Mon, 30 Mar 2026 08:02:13 +0000Psychoeducational schema therapy for psoriasis and atopic dermatitis: a randomized controlled pilot crossover trial.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/psychoeducational-schema-therapy-for-psoriasis-and-atopic-dermatitis-a-randomized-controlled-pilot-crossover-trial-r538/Background and objectivesAtopic dermatitis and psoriasis are chronic inflammatory skin diseases often linked to psychological stress. Integrative care models are lacking. This randomized pilot study aimed to develop and test a psychoeducational intervention for dermatology patients.

Patients and methods

Patients with a PHQ-2 score ≥ 3 at an outpatient inflammation center were randomized into an intervention or control group. The intervention group received three standardized educational sessions focusing on maladaptive schemas, coping strategies, psychoeducation, and emotion-focused techniques (e.g. chair-dialogues, imaginary rescripting).

Results

19 patients received the intervention; 13 were in the control group. Post-intervention, significant improvements were observed in dermatological quality of life (DLQI), subjective well-being (WHO-5), and depressive symptoms (PHQ-9, BDI-II). Psychological benefits were largely independent of disease severity (PASI, EASI). Qualitative feedback highlighted usability, learning specific techniques, and a trusting therapeutic relationship.

Conclusions

A brief psychoeducational intervention significantly reduced psychological stress in dermatology outpatients. Further studies are needed to evaluate long-term effects and broader implementation.

]]>538Mon, 30 Mar 2026 08:02:13 +0000Simulation der Auswirkungen eines edukativen und digitalen Ansatzes unter Verwendung von Patient‐Journey‐Modellen, um praktische Herausforderungen bei der Behandlung der chronischen spontanen Urtikaria in Deutschland zu bewältigenhttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/simulation-der-auswirkungen-eines-edukativen-und-digitalen-ansatzes-unter-verwendung-von-patient%E2%80%90journey%E2%80%90modellen-um-praktische-herausforderungen-bei-der-behandlung-der-chronischen-spontanen-urtikaria-in-deutschland-zu-bew%C3%A4ltigen-r508/No abstract supplied.

]]>508Wed, 11 Mar 2026 05:52:25 +0000Lebensqualität bei Patienten mit vernarbender und nicht vernarbender Alopezie: eine explorative Querschnittsstudiehttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/lebensqualit%C3%A4t-bei-patienten-mit-vernarbender-und-nicht-vernarbender-alopezie-eine-explorative-querschnittsstudie-r507/No abstract supplied.

]]>507Wed, 11 Mar 2026 05:52:25 +0000Erfolgreiche Behandlung einer palmoplantaren Pustulose mit Bimekizumab und topischer Photochemotherapie bei gleichzeitig bestehender Hidradenitis suppurativahttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/erfolgreiche-behandlung-einer-palmoplantaren-pustulose-mit-bimekizumab-und-topischer-photochemotherapie-bei-gleichzeitig-bestehender-hidradenitis-suppurativa-r506/No abstract supplied.

]]>506Wed, 11 Mar 2026 05:52:25 +0000S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - part 2: Specific clinical and comorbid situations.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/s3-guideline-for-the-treatment-of-psoriasis-vulgaris-adapted-from-euroguiderm-part-2-specific-clinical-and-comorbid-situations-r460/Weiterlesen

]]>460Sun, 22 Feb 2026 17:23:04 +0000Wohlbefinden bei Patienten mit Vitiligo mit Beteiligung der sichtbaren Hautareale und der Genitalregion in Deutschland– eine fragebogengestützte Pilotstudiehttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/wohlbefinden-bei-patienten-mit-vitiligo-mit-beteiligung-der-sichtbaren-hautareale-und-der-genitalregion-in-deutschland-eine-fragebogengest%C3%BCtzte-pilotstudie-r449/No abstract supplied.

]]>449Tue, 10 Feb 2026 08:00:26 +0000Schambezogene Störungen bei Patienten mit atopischer Dermatitis und Psoriasis – eine explorative, Querschnitts‐Interviewstudie zu Prävalenz und Korrelaten körperdysmorpher Störungen und sozialer Angststörungenhttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/schambezogene-st%C3%B6rungen-bei-patienten-mit-atopischer-dermatitis-und-psoriasis-eine-explorative-querschnitts%E2%80%90interviewstudie-zu-pr%C3%A4valenz-und-korrelaten-k%C3%B6rperdysmorpher-st%C3%B6rungen-und-sozialer-angstst%C3%B6rungen-r448/No abstract supplied.

Weiterlesen

]]>448Tue, 10 Feb 2026 08:00:26 +0000S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – part 2: Specific clinical and comorbid situationshttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/s3-guideline-for-the-treatment-of-psoriasis-vulgaris-adapted-from-euroguiderm-part-2-specific-clinical-and-comorbid-situations-r447/No abstract supplied.

]]>447Tue, 10 Feb 2026 08:00:26 +0000S3‐Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm – Teil 2: Hilfestellungen für besondere klinische Situationen und bei Vorliegen von Komorbiditätenhttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/s3%E2%80%90leitlinie-zur-therapie-der-psoriasis-vulgaris-adaptiert-von-euroguiderm-teil-2-hilfestellungen-f%C3%BCr-besondere-klinische-situationen-und-bei-vorliegen-von-komorbidit%C3%A4ten-r446/No abstract supplied.

]]>446Tue, 10 Feb 2026 08:00:26 +0000In vivo multiphoton microscopy of psoriasis: A new diagnosis and therapeutic monitoring technique.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/in-vivo-multiphoton-microscopy-of-psoriasis-a-new-diagnosis-and-therapeutic-monitoring-technique-r435/Background and objectivesPsoriasis is a chronic inflammatory skin disease, and noninvasive diagnostic tools are essential for accurate diagnosis and treatment monitoring. Multiphoton microscopy (MPM) enables real-time, noninvasive skin imaging with submicron resolution. This study evaluated the diagnostic accuracy of MPM in psoriasis and its potential application in therapeutic monitoring.

Patients and methods

This prospective observational study enrolled 34 patients with psoriasis. It comprised three parts: (1) analysis of imaging features of lesional and nonlesional skin using multiphoton microscopy (MPM; Transcend Vivoscope); (2) evaluation of the diagnostic performance of MPM parameters compared with reflectance confocal microscopy (RCM); and (3) prospective monitoring of 24 patients treated with Benvitimod (Tapinarof) cream for 8 weeks (T0/T1/T2).

Results

MPM detected psoriasis characteristics (including hyperkeratosis, parakeratosis, an absent stratum granulosum, enlarged nucleus diameter, and absent bright rimming) with comparable diagnostic efficiency to RCM (AUC = 0.838, p < 0.001 vs. 0.824, p < 0.001). Psoriatic lesions showed significant perinuclear fluorescence accumulation compared to healthy skin (p < 0.001). All imaging features improved significantly after 8 weeks of treatment (p < 0.001). PASI/TLS scores showed correlations with the epidermal thickness (r = 0.403/0.492, p < 0.001), nuclear diameter (r = 0.4/0.375, p < 0.001), and fluorescence intensity (r = -0.419/-0.492, p < 0.001).

Conclusions

MPM is a novel and non-invasive imaging technique for psoriasis evaluation and treatment monitoring.

]]>435Tue, 03 Feb 2026 08:49:24 +0000Acne tarda: Recommendations for classification, treatment and care as a result of an expert discussion.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/acne-tarda-recommendations-for-classification-treatment-and-care-as-a-result-of-an-expert-discussion-r424/Weiterlesen

]]>424Sun, 25 Jan 2026 18:42:11 +0000Acne tarda: Empfehlungen zu Einordnung, Therapie und Pflege als Ergebnis einer Expertendiskussionhttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/acne-tarda-empfehlungen-zu-einordnung-therapie-und-pflege-als-ergebnis-einer-expertendiskussion-r423/No abstract supplied.

Weiterlesen

]]>423Sun, 25 Jan 2026 18:42:11 +0000Treatment of Generalized Pustular Psoriasis with Abrocitinib: A Case Report.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/treatment-of-generalized-pustular-psoriasis-with-abrocitinib-a-case-report-r422/No abstract supplied.

]]>422Sun, 25 Jan 2026 18:42:11 +0000Efficacy of upadacitinib in palmoplantar pustulosis case series highlights the complex immune response patterns.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/efficacy-of-upadacitinib-in-palmoplantar-pustulosis-case-series-highlights-the-complex-immune-response-patterns-r421/Background and objectivesPalmoplantar pustulosis (PPP) is a chronic and refractory inflammatory skin disorder with unclear pathogenesis.

Patients and methods

Ten PPP patients treated with upadacitinib were monitored to assess efficacy and safety. Immunofluorescence and immunohistochemistry were employed to evaluate Th1, Th2, and Th17 cell expressions, along with their associated cytokines in lesions on palms or soles from 16 PPP patients, 10 chronic eczema (CE) patients, 10 psoriasis vulgaris (PV) patients, and 7 healthy controls (HC).

Results

In PPP patients receiving upadacitinib, the shortest time to achieve PPPASI75 and PPPASI90 was 4 weeks and 8 weeks, respectively. The rates of patients achieving PPPASI90 at week 16, week 24, and week 52 was 70 %, 100 %, and100 %, respectively. Th1 cells and IFN-γ levels in PPP were comparable to CE and PV, and higher than HC. Th2 cells, IL-4, and IL-13 levels in PPP were similar to CE, and greater than HC and PV. Th17 cells, IL-17, and IL-36γ levels in PPP were comparable to PV, and more abundant than HC and CE.

Conclusions

Upadacitinib is a safe and effective option for PPP patients, which may be attributed to the complex Th1, Th2, and Th17 inflammatory responses associated with PPP.

]]>421Sun, 25 Jan 2026 18:42:11 +0000